In this exploratory study, patients with stage 1-3 adenocarcinoma of the colon with no signs of distant metastases will be treated with short-term immunotherapy + novel IO combinations (i.e. anti-IL 8, COX2-inhibitors, anti-LAG3). This treatment will be given during the window period until surgical resection of the tumor. The duration of treatment will be in between approximately 6 and 12 weeks.
Signed written informed consent
Patients at least 18 years of age
Non-metastatic adenocarcinoma of the colon (and rectosigmoid considered as nonrectal and not undergoing neoadjuvant treatment)
No signs of distant metastases on CT-scan and physical examination;
No signs of distant metastases
No signs of obstruction or macroscopic bleeding or suspicion of perforation
Colonoscopy must be performed after registration to obtain study-specific biopsies. If biopsies are not possible, patients cannot be included in the study
WHO performance status of 0 or 1
7
Treatment groupsSee each treatment group below.
The Netherlands Cancer Institute
Lead sponsor
Bristol-Myers Squibb
Collaborator